A high-throughput microfluidic mechanoporation platform to enable intracellular delivery of cyclic peptides in cell-based assays.

Publication Year: 2023

DOI:
10.1002/btm2.10542

PMCID:
PMC10487316

PMID:
37693049

Journal Information

Full Title: Bioeng Transl Med

Abbreviation: Bioeng Transl Med

Country: Unknown

Publisher: Unknown

Language: N/A

Publication Details

Subject Category: Engineering, Biomedical

Available in Europe PMC: Yes

Available in PMC: Yes

PDF Available: No

Transparency Score
3/6
50.0% Transparent
Transparency Indicators
Click on green indicators to view evidence text
Core Indicators
Evidence found in paper:

"data s1."

Code Sharing
Evidence found in paper:

"CONFLICT OF INTEREST STATEMENT All authors that are present or former employees of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., Rahway, NJ or MSD International, Singapore may hold stocks and/or stock options in Merck & Co., Inc., Rahway, NJ. Srinivasaraghavan Kannan and Chandra S. Verma are co‐founders of Sinopsee Therapeutics and Aplomex; the current work does not have a conflict."

Funding Disclosure
Protocol Registration
Open Access
Paper is freely available to read
Additional Indicators
Replication
Novelty Statement
Assessment Info

Tool: rtransparent

OST Version: N/A

Last Updated: Aug 05, 2025